Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

                                 January 3, 2008
                Date of Report (Date of earliest event reported)

                                 ANTIGENICS INC.
             (Exact name of registrant as specified in its charter)

            DELAWARE                    000-29089              06-1562417
  (State or other jurisdiction         (Commission           (IRS Employer
        of incorporation)              File Number)       Identification No.)

         162 Fifth Avenue, Suite 900
                 New York, NY                                    10010
   (Address of principal executive offices)                    (Zip Code)

              (Registrant's telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[_]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[_]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR

[_]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[_]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

Item 8.01   Other Events

     On January 3, 2008, Antigenics Inc. announced that Acambis has released
results from a Phase 1 study of its ACAM-FLU-A(TM) vaccine, which contains
Antigenics' QS-21 Stimulon(R) adjuvant. Overall, the trial results demonstrated
that ACAM-FLU-A was well tolerated and capable of stimulating an immune
response. Although immune responses were observed in all groups that received
vaccine, the highest immune response was observed in the group vaccinated with
ACAM-FLU-A plus QS-21 adjuvant. In this group, 90 percent of subjects generated
virus-specific antibodies following immunization. Based on these results,
Acambis exercised its option for a commercial license to QS-21. Under the terms
of the agreement, Antigenics is entitled to receive future milestone payments
and product royalties in the event of successful development and
commercialization of ACAM-FLU-A.

     The full text of the press release issued in connection with the
announcement is being furnished as Exhibit 99.1 to this current report on Form

Item 9.01   Financial Statements and Exhibits

      (d) Exhibits

      The following exhibit is furnished herewith:

                    99.1 Press Release dated January 3, 2008


Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                        ANTIGENICS INC.

Date: January 3, 2008

                                  By:    /s/ Garo H. Armen

                                         Garo H. Armen, Ph.D.
                                         Chairman and Chief Executive Officer


Exhibit No. Description of Exhibit
----------- ----------------------

99.1        Press Release dated January 3, 2008